12/2
08:05 am
sgmo
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
Medium
Report
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
11/28
01:23 am
sgmo
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics [Yahoo! Finance]
Low
Report
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics [Yahoo! Finance]
11/21
09:38 am
sgmo
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease [Yahoo! Finance]
11/21
08:05 am
sgmo
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
Low
Report
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
11/15
01:42 am
sgmo
Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at
Wall St
Medium
Report
Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at
Wall St
11/10
01:51 am
sgmo
Why Sangamo Therapeutics (SGMO) Is Down 21.1% After Steep Q3 Revenue Drop and Nasdaq Compliance Extension [Yahoo! Finance]
Medium
Report
Why Sangamo Therapeutics (SGMO) Is Down 21.1% After Steep Q3 Revenue Drop and Nasdaq Compliance Extension [Yahoo! Finance]
11/8
07:05 pm
sgmo
Why The Narrative Around Sangamo Therapeutics Is Shifting After Recent Analyst and FDA Updates [Yahoo! Finance]
Medium
Report
Why The Narrative Around Sangamo Therapeutics Is Shifting After Recent Analyst and FDA Updates [Yahoo! Finance]
11/7
08:07 am
sgmo
Sangamo Therapeutics (NASDAQ:SGMO) had its "equal weight" rating reaffirmed by analysts at Barclays PLC. They now have a $1.00 price target on the stock, down previously from $5.00.
Low
Report
Sangamo Therapeutics (NASDAQ:SGMO) had its "equal weight" rating reaffirmed by analysts at Barclays PLC. They now have a $1.00 price target on the stock, down previously from $5.00.
11/6
08:01 am
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
High
Report
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
10/30
04:01 pm
sgmo
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
Medium
Report
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
10/30
10:39 am
sgmo
We're Hopeful That Sangamo Therapeutics (NASDAQ:SGMO) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Sangamo Therapeutics (NASDAQ:SGMO) Will Use Its Cash Wisely [Yahoo! Finance]